We demonstrated that MTAP-loss is potentially one of the most prevalent targetable mutations in PDAC, IHCC, and GEAC, with prevalence of 22%, 15%, and 8.7%, respectively.29-31MTAP-loss is extremely uncommon in HCC and CRC though, making it unlikely that clinical trials of MTAP-loss will specifically seek to enroll patients with these cancers. The gene discussed is MTAP; the disease is cancer.